| Name | Title | Contact Details |
|---|---|---|
Laura Sarkis |
Sr Director Assistant General Counsel | Profile |
Arunabha Bhoumik |
Vice President, Associate General Counsel | Head, General Litigation and Government Investigations | Profile |
Donna Gambaccini |
Director, Corporate Counsel | Profile |
Alicia Alterbaum |
Director, Corporate Counsel | Profile |
Paul Cardon |
Director Corporate Counsel | Profile |
Athersys is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Symic is developing a new category of therapeutics that offer an exciting and biologically innovative approach to treating disease. While it is clear that cells play an important role in tissue inflammation and regeneration, it is also known that the extracellular matrix (ECM) plays an equally critical role in maintaining healthy tissue. The ECM is the non-cellular component of the body’s tissues, and proteoglycans are important structural and functional macromolecules native to the ECM that are known to protect against tissue degradation and promote healing during illness or injury. Recognizing the importance of proteoglycans in many acute and chronic disease states, Symic developed a library of proprietary, ECM-specific compounds that mimic the protective effect of natural proteoglycans. For controlled injuries (e.g. incisions, balloon angioplasty), Symic’s ECM-specific compounds allow for local application, enhancing their ability to attenuate inflammation and reduce scarring only at the site of injury. In disease states known for chronic inflammation involving the ECM (e.g. cartilage in osteoarthritis), Symic’s technology can disrupt the cycle of degradation-inflammation by directly targeting and protecting the injured ECM. The ECM plays a critical role in many acute and chronic disease states, many of which have limited or no effective therapeutic options. Symic plans to advance its compounds in a variety of therapeutic areas with unmet clinical needs.
Legacy Health System is an Oregon-based not-for-profit, tax-exempt corporation that includes five full-service hospitals and a children's hospital.
BELLUS Health is a clinical stage biotechnology company developing novel therapeutics for the treatment of chronic cough and other chronic disorders triggered by hypersensitization.
Cleveland Diagnostics is developing a breakthrough technology to discover a new class of diagnostics tests with high sensitivity and specificity for many cancers – early on, when cancer is still curable.